Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2000
11/14/2000US6147082 Chalcones having antiproliferative activity
11/14/2000US6147080 Inhibitors of p38
11/14/2000US6147079 N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate
11/14/2000US6147075 Analgesics; psychological disorders
11/14/2000US6147065 14-α, 17-α-C2 bridged norprogesterone derivatives
11/14/2000US6147064 Oral 1α-hydroxyprevitamin D in composition and method for treating psoriasis
11/14/2000US6147063 Therapeutic substituted guanidines
11/14/2000US6147061 Antiarthritic agents; anticancer agents; oral diseases
11/14/2000US6147050 5-lipoxygenase-activating protein II
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/14/2000US6146829 Gapped 2' modified oligonucleotides
11/14/2000US6146658 Prodrugs, their preparation and use as pharmaceuticals
11/14/2000US6146636 Substance P antagonists comprising rosaceae plant extracts
11/14/2000US6146630 Inhibitors for the adhesion of lymphocytes to glandular cells
11/14/2000US6146626 Mixtures of purified enzymes from clostridium histolyticum, comprising collagenase with hexapeptide as a substrate, collagenase using azocoll as substrate and elastase, used as wound healing agent
11/14/2000CA2308826A1 Combination therapy for the treatment of migraine
11/14/2000CA2308824A1 Combination therapy for the treatment of migraine
11/14/2000CA2308323A1 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
11/14/2000CA2179207C Parathyroid hormone formulation
11/14/2000CA1341139C Tetrahydropyridine oxime cholinergic agents and method of treatment
11/12/2000CA2721484A1 Dopamine transporter imaging agents
11/10/2000CA2307446A1 Complex for transferring an anionic substance of interest into a cell
11/09/2000WO2000067025A1 Determination of complex phospholipid/lipid structures using synthetic fluorescence-marked acylglycerides
11/09/2000WO2000066766A1 Optical probes and assays
11/09/2000WO2000066758A1 Expression of heterologous genes from an ires translational cassette in retroviral vectors
11/09/2000WO2000066752A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophati dylinositol-modified carboypeptidase g2 and a cell surface targettng signal peptide
11/09/2000WO2000066737A1 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY
11/09/2000WO2000066736A1 Growth factor homolog zvegf4
11/09/2000WO2000066735A2 Human ion channel proteins
11/09/2000WO2000066709A2 Zymogen activation system
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066618A1 Integrin receptor antagonists
11/09/2000WO2000066611A1 Steroid derivatives
11/09/2000WO2000066609A1 Oligonucleotides having a-dna form and b-dna form conformational geometry
11/09/2000WO2000066589A1 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
11/09/2000WO2000066584A1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
11/09/2000WO2000066583A1 Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
11/09/2000WO2000066581A1 Cyanopyrroles as progesterone receptor agonists
11/09/2000WO2000066572A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000WO2000066571A1 Cyclocarbamate derivatives as progesterone receptor modulators
11/09/2000WO2000066570A1 Cyclothiocarbamate derivatives as progesterone receptor modulators
11/09/2000WO2000066567A1 Pyrimidinone compounds
11/09/2000WO2000066566A1 Pyrimidine compounds
11/09/2000WO2000066564A1 Benzimidazolones and analogues and their use as progesterone receptor ligands
11/09/2000WO2000066563A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands
11/09/2000WO2000066558A1 Piperazine derivatives useful as ccr5 antagonists
11/09/2000WO2000066557A1 New compounds
11/09/2000WO2000066556A1 Indoline derivatives as progesterone antagonists
11/09/2000WO2000066555A1 Thio-oxindole derivatives
11/09/2000WO2000066551A1 Cyclic amide compounds, process for the preparation of the same and uses thereof
11/09/2000WO2000066550A1 New compounds
11/09/2000WO2000066522A1 Glucocorticoid receptor modulators
11/09/2000WO2000066182A1 X-ray guided drug delivery
11/09/2000WO2000066175A2 Conjugates as therapies for cancer and prostate diseases
11/09/2000WO2000066156A1 Death domain containing receptor 5
11/09/2000WO2000066148A1 Novel proteins
11/09/2000WO2000066141A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
11/09/2000WO2000066135A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000WO2000066134A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000WO2000066131A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide
11/09/2000WO2000066130A1 Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate
11/09/2000WO2000066123A1 Synergistic combination comprising roflumilast and a pde-3 inhibitor
11/09/2000WO2000066119A1 Novel prolines as antimicrobial agents
11/09/2000WO2000066114A1 Treatment of female arousal disorder
11/09/2000WO2000066112A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics
11/09/2000WO2000066111A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
11/09/2000WO2000066110A1 Glycine cleavage system inhibitors as potential antipsychotics
11/09/2000WO2000066104A2 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000WO2000066102A2 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
11/09/2000WO2000066099A2 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
11/09/2000WO2000066093A2 Combined preparations comprising morpholine anthracyclines and anticancer agent
11/09/2000WO2000066086A1 Anti-inflammatory bioactive glass particulates
11/09/2000WO2000066078A1 Cosmetic and/or dietetic composition comprising a mixture of lycopene and olive leaf extract
11/09/2000WO2000051968A8 Method for the preparation of a chiral-beta-amino ester
11/09/2000WO2000039087A3 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000038661A3 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
11/09/2000WO2000032624A3 Uncoupling protein 5 - ucp5
11/09/2000WO2000031238A3 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
11/09/2000WO2000030668A3 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
11/09/2000WO2000029553A9 Bioengineered tissue constructs and methods for producing and using them
11/09/2000WO2000028034A3 Cytokine signal regulators
11/09/2000WO2000024771A3 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
11/09/2000WO2000023565A3 Novel neuropilin/growth factor binding and uses thereof
11/09/2000WO2000019989A3 Use of catechol derivatives as proteinase inhibitors
11/09/2000WO2000015785A3 GENE MODIFICATION IN THE GENE FOR THE DIE Gβ3-SUB-UNIT OF HUMAN G-PROTEIN
11/09/2000WO2000004050A3 Neurotrophic growth factor
11/09/2000WO2000001349A3 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
11/09/2000WO1999056769A3 Inhibition of helicobacter pylori proliferation
11/09/2000WO1999055868A3 Fizz proteins
11/09/2000WO1999045907A9 Metal chelators for use in the treatment of alzheimer's disease
11/09/2000DE19922444A1 Verfahren zur Behandlung von TNF-Rezeptor vermittelten Krankheiten A method for the treatment of TNF-receptor-mediated diseases
11/09/2000DE19920936A1 Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung Heterocyclic substituted benzimidazoles, their preparation and application
11/09/2000CA2742143A1 2-3-dihydroxypropyl 12-(7-nirobenzo[1,2,3]oxadiazol-4-ylamino)dodecanoates and a process for the preparation thereof
11/09/2000CA2388658A1 1-amino triazolo[4,3-a]quinazolin-5-ones and or -5-thiones inhibiting phosphodiesterase iv
11/09/2000CA2373225A1 Oligonucleotides having a-dna form and b-dna form conformational geometry
11/09/2000CA2372923A1 Dna encoding snorf36a and snorf36b receptors
11/09/2000CA2372907A1 Zymogen activation system
11/09/2000CA2372803A1 Variants of traf2 which act as an inhibitor of tnf-alpha (tnf .alpha.) signaling pathway
11/09/2000CA2372772A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
1 ... 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 ... 1564